Skip to main content
Premium Trial:

Request an Annual Quote

Inscripta Acquires Infinome Biosciences, Sestina Bio

NEW YORK – Genome editing firm Inscripta said on Wednesday that it has acquired two synthetic biology firms, Infinome Biosciences and Sestina Bio, for an undisclosed amount. The moves suggest the firm has pivoted to biomanufacturing, away from genome editing instrumentation.

Infinome, based in Boulder, Colorado, has developed a platform for rapidly engineering microbial strains, dubbed GenoScaler. Inscripta invested in Infinome in March 2021, calling it the firm's "first subsidiary" at the time.

Sestina Bio, located in Pleasanton, California, has developed an approach for building and identifying strains that can withstand scale-up to the levels needed for commercial biomanufacturing. In October, the firms announced that Sestina Bio had used Inscripta's Onyx genome editing platform to develop a microbial strain that can produce bakuchiol, a potential skincare ingredient.

"Tackling the unprecedented opportunity to improve global health and sustainability through biomanufacturing requires a strong combination of talent, experience, technology, and commercial assets," Inscripta CEO Sri Kosaraju said in a statement. "Infinome and Sestina Bio allow us to advance our strategy and complement our technological innovation and capabilities needed for creating the next generation of biobased manufacturing products and processes."

Financial and other terms of the deals were not disclosed.

The acquisitions and accompanying statement suggest that Inscripta has shifted its focus, as it was rumored to have done in December when it laid off at least 43 people and closed its San Diego and Boulder, Colorado, facilities. The firm is now based in Pleasanton, California.

Inscripta's statement also noted that Infinome has partnered with Kalsec, a food and beverage ingredient maker, to develop and commercialize multiple biomanufactured products.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.